Philips secures FDA 510(k) clearance for next-generation reusable SpO₂ clip sensor

USA—Royal Philips has secured US Food and Drug Administration (FDA) 510(k) clearance for its next-generation reusable Philips SpO₂ clip sensor, which is designed to provide clinicians with more consistent oxygen saturation measurements across diverse patient populations and clinical settings.

The clearance strengthens Philips’ pulse oximetry portfolio as the company continues to invest in sensor technology to support reliable monitoring of patients’ oxygenation status.

Improved signal quality and measurement accuracy

The new reusable sensor features internal optical refinements that improve signal quality and measurement consistency.

According to Philips, these enhancements are intended to support reliable SpO₂ measurements under a range of clinical and physiological conditions.

In desaturation studies, the sensor recorded an Accuracy Root Mean Square (ARMS) value of 1.6%, compared with the 3% performance level recommended by the International Organization for Standardization (ISO) and recognized by the FDA.

The company said the sensor also maintained consistent accuracy across different skin tones.

In evaluations covering an arterial oxygen saturation (SaO₂) range of 85% to 100%, the difference in accuracy between the lightest and darkest skin pigmentation groups assessed was less than 0.5%.

Philips said the findings reflect its approach to sensor development, which combines optical engineering with testing across diverse patient populations.

“Providing clinicians with reliable data to deliver better care to more people is at the heart of everything we do,” said Sachin Chaudhari, Category Leader, Clinical Measurements and Specialty Monitoring at Philips.

“This FDA clearance reflects our ongoing investment in advancing sensor technology and rigorous validation practices, and we’ll continue applying these innovations across our pulse oximetry portfolio so clinicians can make care decisions with even greater confidence,” he added.

Validation across diverse clinical settings

Pulse oximetry remains one of the most widely used monitoring technologies in healthcare, providing clinicians with information about a patient’s oxygenation status.

However, factors such as physiological differences, clinical conditions and technical variables can affect signal quality and measurement performance.

To address these challenges, Philips said it uses a comprehensive validation programme to evaluate its pulse oximetry sensors across diverse patient populations and a broad range of physiological and clinical conditions.

The programme includes assessments involving different skin tones and is designed to align with evolving FDA recommendations and applicable international standards established by organizations such as ISO and the International Electrotechnical Commission (IEC).

Philips also continues to work with clinicians, researchers, regulators and standards organizations to advance the science supporting pulse oximetry and strengthen validation practices.

The FDA-cleared reusable Philips SpO₂ clip sensor is expected to become available in select markets worldwide later this year.